Holen Sie sich die Stockscreener-App
12.37
0.82%
-0.0726
Schlusskurs vom Vortag:
$12.44
Offen:
$12.44
24-Stunden-Volumen:
915.76K
Relative Volume:
0.79
Marktkapitalisierung:
$730.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-3.3516
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
+20.96%
1M Leistung:
+71.60%
6M Leistung:
+40.84%
1J Leistung:
-2.85%
1-Tages-Spanne:
$11.89
$12.88
1-Wochen-Bereich:
$10.01
$12.88
52-Wochen-Spanne:
$5.68
$13.33
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Vergleichen Sie CGEM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
12.37 | 734.91M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 - MarketBeat
Wedbush Raises Price Target on CGEM to $34, Maintains Outperform - GuruFocus
CGEM: CLN-049 demonstrates strong efficacy and safety in AML, advancing toward pivotal trials - TradingView
Cullinan Therapeutics (NASDAQ:CGEM) Trading 9.3% HigherWhat's Next? - MarketBeat
Cullinan Oncology stock soars after promising AML treatment results By Investing.com - Investing.com UK
Cullinan’s leukemia drug shows promising results in clinical trial By Investing.com - Investing.com South Africa
Cullinan Therapeutics Presents Promising CLN-049 Data - TipRanks
Cullinan Therapeutics (CGEM) Reveals Encouraging Phase 1 Data fo - GuruFocus
Cullinan Therapeutics Showcases Compelling Clinical Data in - GlobeNewswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Investment Review: Will Cullinan Therapeutics Inc stock deliver better than expected guidance2025 Dividend Review & Breakout Confirmation Alerts - BỘ NỘI VỤ
Why Cullinan Therapeutics Inc. stock could benefit from AI revolution2025 Volatility Report & Weekly Hot Stock Watchlists - Newser
How Cullinan Therapeutics Inc. stock benefits from strong dollarJuly 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%What's Next? - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - Setenews
How Cullinan Therapeutics Inc. stock responds to policy changesEarnings Risk Summary & Free Weekly Watchlist of Top Performers - Newser
FDA grants fast track designation to Cullinan’s AML therapy By Investing.com - Investing.com Australia
Cullinan Oncology stock rises after FDA Fast Track designation for leukemia drug - Investing.com Canada
Cullinan Therapeutics receives FDA fast track designation for CLN-049 - marketscreener.com
CGEM Receives FDA Fast Track for CLN-049 in Leukemia Treatment - GuruFocus
FDA grants fast track designation to Cullinan’s AML therapy - Investing.com India
Cullinan Therapeutics' CLN-049 Receives FDA Fast Track Designation for Treatment of Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - Yahoo Finance
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells 4,000 Shares of Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 7.6%Should You Sell? - MarketBeat
Cullinan Oncology stock price target raised to $36 at Jones Trading - Investing.com Nigeria
Why Cullinan Therapeutics (CGEM) Is Up 38.1% After FDA Filing for EGFR-mutant Lung Cancer Drug - Sahm
Buy Rating for Cullinan Therapeutics Driven by Promising AML Treatment Developments and Strong Market Potential - TipRanks
Foresite Capital Management VI LLC Lowers Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer (PR Newswire) - Aktiellt
Cullinan Therapeutics (NASDAQ:CGEM) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Investors Purchase High Volume of Call Options on Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
Is Cullinan Therapeutics Inc (CGEM) positioned for future growth? - Setenews
Cullinan Oncology stock price target raised to $38 at BTIG on promising AML data - Investing.com Canada
Taiho, Cullinan file rolling NDA on phase I/II zipalertinib data - BioWorld MedTech
BTIG Maintains Cullinan Therapeutics (CGEM) Buy Recommendation - Nasdaq
Cullinan Therapeutics (CGEM) Receives PT Upgrade from BTIG Analy - GuruFocus
Cullinan Therapeutics price target raised to $38 from $32 at BTIG - TipRanks
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Cullinan Management Ends Development of CLN-617 - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $26.00 - Defense World
Wall Street Zen Upgrades Cullinan Therapeutics (NASDAQ:CGEM) to Hold - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Wedbush Reiterates “Outperform” Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics' (CGEM) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Cullinan TherapeuticsCullinan Amber notified MIT decision to terminate exclusive patent license agreement for CLN-617 - marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 8.5% Following Analyst Upgrade - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 8.5% After Analyst Upgrade - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Otsuka units file for US approval for zipalertinib - The Pharma Letter
Cullinan Therapeutics (CGEM) Advances with FDA Acceptance for Lu - GuruFocus
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):